{"title":"单克隆抗体药物治疗多发性硬化症和视神经脊髓炎谱系障碍","authors":"Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno","doi":"10.1111/cen3.12725","DOIUrl":null,"url":null,"abstract":"<p>In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\",\"authors\":\"Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno\",\"doi\":\"10.1111/cen3.12725\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.</p>\",\"PeriodicalId\":10193,\"journal\":{\"name\":\"Clinical and Experimental Neuroimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Neuroimmunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12725\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder
In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
